Sofinnova Partners closes €725 million second crossover fund
Sofinnova Partners closed its second crossover fund at €725 million, about $815 million, to invest in late-stage life sciences companies advancing toward global commercialization.
By Olivia Hart
3 min read

What's News
- Sofinnova Partners closed Sofinnova Crossover II with €725 million, approximately $815 million.
- The second crossover fund targets late-stage life sciences companies moving through clinical development, international expansion and commercialization.
- Crossover investments can span private and public companies and multiple development stages.
- Sofinnova Partners operates from Paris, London and Milan.
- The firm will reuse the disciplined approach from its first crossover fund while pursuing a larger opportunity set.
By Olivia Hart
What is Sofinnova Crossover II funding?
Sofinnova Partners has closed its second crossover fund with €725 million, approximately $815 million, according to the firm. The vehicle, named Sofinnova Crossover II, will invest in late-stage life sciences companies progressing through clinical development, international expansion and commercialization.
Sofinnova Partners said the fund will serve companies that have moved beyond early scientific discovery. Those companies need funding for later clinical trials, commercial preparation and global market entry, according to the firm.
The announcement does not name any portfolio companies or disclose investment sizes, valuations, a target number of holdings or an expected holding period. Takeaway: The €725 million is earmarked for late-stage businesses that need money for later trials, commercial preparation and global market entry.
Why does the fund use a crossover structure?
Crossover investing can span private and public companies, according to Sofinnova Partners. That structure allows the fund to support businesses through multiple stages of development, rather than tying capital to one type of issuer or a single round.
Sofinnova Partners said crossover capital can be available when public biotechnology markets or traditional financing sources may be less receptive. The firm did not specify which financing conditions it expects to exploit or how the €725 million would be paced across investments. Takeaway: The structure widens financing access, but deployment has no stated timetable or conditions.
What is Sofinnova’s case for Europe?
“The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets.
Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization.”
— Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners
Papiernik's statement links the fund's size to the maturity of Europe's life sciences ecosystem and to rising demand for capital. He also asserts that Europe is producing more world-class companies with the science, clinical validation and leadership needed to compete globally.
Sofinnova Partners supplied no independent evidence for those claims in the announcement. It did not compare Crossover II with the first fund's size, disclose historical returns or identify prior investments. Takeaway: The case rests on Europe's maturation, not on evidence presented about past outcomes.
How will Sofinnova deploy the capital?
“We continue to see exceptional opportunities emerging across European life sciences.
Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage.
With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.”
— Kinam Hong, Partner at Sofinnova Partners
Hong said Sofinnova Partners will apply the disciplined investment approach used for its first crossover fund while pursuing a larger set of opportunities. The firm operates from Paris, London and Milan.
The announcement does not explain what that discipline means in practice, name any investments or provide a deployment schedule. Takeaway: The second fund promises continuity with the first, but the announcement leaves its execution criteria undefined.
What will determine whether the thesis works?
Sofinnova Crossover II will be judged on the outcomes its partners emphasize: advancing companies through later clinical trials, commercial preparation and global market entry. Neither Papiernik nor Hong provided performance data for the first fund, a target number of investments or a timetable for deploying the €725 million.
The strategy offers companies access to capital during periods when public biotechnology markets or traditional financing sources may be less receptive, according to Sofinnova Partners. Takeaway: The next test is whether Sofinnova can identify investments that use the €725 million to turn European scientific and clinical strength into commercialization on a global stage.
Source: pulse2.com
More from Olivia Hart
Show full bio
Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,404 articles